product name Dacarbazine
Description: Dacarbazine (also known as DTIC, DTIC-Dome) is an antineoplastic chemotherapy drug used in the treatment of various cancers, including advanced melanoma (primary use), Hodgkin lymphoma, sarcoma, and islet cell carcinoma of the pancreas. Treatment of Dacarbazine sensitizes melanomas to lysis of peptide-specific CTL and it is is mediated through Fas-independent pathway. Dacarbazine belongs to the class of alkylating agents, which destroy cancer cells by adding an alkyl group to its DNA.
References: J Exp Clin Cancer Res. 2000;19(1):21-34; J Immunol. 2004;172(7):4599-608; Oncol Lett. 2013;6(1):69-74.
182.18
Formula
C6H10N6O
CAS No.
4342-03-4
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 3 mg/mL (16.5 mM)
Water: <1 mg/mL
Ethanol: <1 mg/mL
Solubility (In vivo)
0.5% CMC Na: 30mg/mL
Synonyms
DTIC-Dome
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19412884
| In Vitro |
In vitro activity: Treatment of Dacarbazine sensitizes melanomas to lysis of peptide-specific CTL and it is is mediated through Fas-independent pathway. Kinase Assay: Cell Assay: Apotosis assay: UACC903 (UACC) cells treated with or without DTIC (20 μM) for 48 h are incubated with agonist anti-Fas Ab, CH-11 (500 ng/ml), for 5 and 16 h, respectively. To distinguish whether death/apoptosis is mediated by FasR, blocking anti-Fas Ab ZB4 (2 mg/ml) is added in the corresponding groups. At the end of incubation, cells are harvested and stained with propidium iodide and FITC-annexin V (BD PharMingen) for detecting apoptosis according to the instruction provided by the company. Ten thousand cells from each group are collected, and dead and apoptotic cells are analyzed without gating using CellQuest software. |
|---|---|
| In Vivo | Treatment of combination of Axitinib and DTIC demonstrates significant antitumor activity against melanoma flank xenografts, reduces tumor cell proliferation and decreases the area of tumor necrosis and increases apoptosis. It also reduces meta-tasis-related factors and prolongs lifespan in mice |
| Animal model | B16F1 melanoma xenograft model(C57BL/6 mice background) |
| Formulation & Dosage | Dissolved in 0.9% sodium chloride; 80 mg/kg; i.p. injection |
| References | J Exp Clin Cancer Res. 2000 Mar;19(1):21-34; J Immunol. 2004 Apr 1;172(7):4599-608; Oncol Lett. 2013 Jul;6(1):69-74. |
